Gregory M. Haidemenos MD

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Breast Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer

Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cancer Type: Breast Cancer

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type: Melanoma

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type: Solid Tumor

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Solid Tumor

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Solid Tumor

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type: Solid Tumor

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Unknown Primary

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Unknown Primary

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Unknown Primary

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Unknown Primary

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Unknown Primary

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Unknown Primary

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Unknown Primary

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Unknown Primary

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Unknown Primary

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Unknown Primary